Watson Pharma Private Limited — Hydrochlorothiazide Exporter Profile
Indian Pharmaceutical Exporter · #10 for Hydrochlorothiazide · $4.1M export value · DGFT Verified
Watson Pharma Private Limited is the #10 Indian exporter of Hydrochlorothiazide with $4.1M in export value and 102 verified shipments. Watson Pharma Private Limited holds a 1.0% market share in Hydrochlorothiazide exports across 3 countries. The company exports 14 pharmaceutical products worth $63.4M across 7 therapeutic categories.
Watson Pharma Private Limited — Hydrochlorothiazide Export Profile: Buyers & Destinations
Where Does Watson Pharma Private Limited Export Hydrochlorothiazide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $3.2M | 87 | 88.6% |
| BULGARIA | $412.8K | 13 | 11.4% |
| CZECH REPUBLIC | $289 | 2 | 0.0% |
Watson Pharma Private Limited exports Hydrochlorothiazide to 3 countries. The largest destination is UNITED STATES accounting for 88.6% of Watson Pharma Private Limited's Hydrochlorothiazide shipments, followed by BULGARIA (11.4%) and CZECH REPUBLIC (0.0%). These destinations reflect Watson Pharma Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Hydrochlorothiazide from Watson Pharma Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACTAVIS LABORATORIES FL INC | UNITED STATES | $1.4M | 35 |
| ACTAVIS LABORATORIES FL, INC. | UNITED STATES | $1.4M | 34 |
| BALKANPHARMA DUPNITSA AD | BULGARIA | $412.8K | 13 |
| TEVA PHARMACEUTICALS USA, INC. | UNITED STATES | $200.0K | 4 |
| ACTAVIS LABORATORIES FL, INC | UNITED STATES | $100.0K | 2 |
| ACTAVIS LABORATORIES FL INC. | UNITED STATES | $100.0K | 2 |
| TEVA CZECH INDUSTRIES S.R.O. | CZECH REPUBLIC | $289 | 2 |
| WATSON THERAPEUTICS INC. | UNITED STATES | $3 | 1 |
| TEVA PHARMACEUTICALS | UNITED STATES | $0 | 9 |
Watson Pharma Private Limited supplies Hydrochlorothiazide to 9 buyers globally. The largest buyer is ACTAVIS LABORATORIES FL INC (UNITED STATES), followed by ACTAVIS LABORATORIES FL, INC. (UNITED STATES) and BALKANPHARMA DUPNITSA AD (BULGARIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Hydrochlorothiazide Export Value and How Much Does Watson Pharma Private Limited Contribute?
India exported $119.2M worth of Hydrochlorothiazide through 6,947 shipments from 403 suppliers to 149 countries, serving 1,130 buyers globally. Watson Pharma Private Limited contributes $4.1M to this total, accounting for 1.0% of India's Hydrochlorothiazide exports. Watson Pharma Private Limited ships Hydrochlorothiazide to 3 countries through 9 buyers.
What Is the Average Shipment Value for Watson Pharma Private Limited's Hydrochlorothiazide Exports?
Watson Pharma Private Limited's average Hydrochlorothiazide shipment value is $40.0K per consignment, based on 102 shipments totaling $4.1M. The largest destination is UNITED STATES (88.6% of Watson Pharma Private Limited's Hydrochlorothiazide exports).
How Does Watson Pharma Private Limited Compare to Other Indian Hydrochlorothiazide Exporters?
Watson Pharma Private Limited ranks #10 among 403 Indian Hydrochlorothiazide exporters with a 1.0% market share. The top 3 exporters are MACLEODS PHARMACEUTICALS LTD ($25.4M), UNICHEM LABORATORIES LIMITED ($21.3M), MYLAN LABORATORIES LIMITED ($16.4M). Watson Pharma Private Limited processed 102 shipments to 3 destination countries.
What Hydrochlorothiazide Formulations Does Watson Pharma Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABL | $900.0K | 18 |
| HYDROCHLOROTHIAZIDE CAPSULES USP 12.5 MG | $459.5K | 16 |
| TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABLETS USP 37.5MG/25MG Batch no- 1123501091 MANUFACTURING Date 26-09.10.2023 Expiry Date 3 | $100.0K | 2 |
| TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABLETS USP 37.5MG/25MG Batch no- 1123501092 MANUFACTURING Date 26-09.10.2023 Expiry Date 3 | $100.0K | 2 |
| NEBIVOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS 5MG/25MG 12 KG ( Batch No.1125500272 Mfg Date.12.03.2025 Expiry | $72.4K | 2 |
| NEBIVOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS 5MG/12.5MG 12 KG ( BatchNo.1125500270 Mfg Date. 12.03.2025 Expi | $68.2K | 2 |
| NEBIVOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS 5MG/12.5MG 12 KG ( BatchNo.1125500271 Mfg Date.12.03.2025 Expir | $67.0K | 2 |
| TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABLETS USP 37 5MG 25MG Batch No 1123500194Mfg Date 06 02 2023 Expiry Date 31 01 2 | $50.0K | 1 |
| TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABLETS USP 37 5MG 25MG Batch No 1123500007Mfg Date 03 01 2023 Expiry Date 31 12 2 | $50.0K | 1 |
| TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABLETS USP 37 5MG 25MG Batch No 1122500807Mfg Date 13 08 2022 Expiry Date 31 07 2 | $50.0K | 1 |
Watson Pharma Private Limited exports 59 distinct Hydrochlorothiazide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TRIAMTERENE AND HYDROCHLOROTHIAZIDE TABL with 18 shipments worth $900.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Hydrochlorothiazide to Key Markets
What Watson Pharma Private Limited must comply with to export Hydrochlorothiazide to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Watson Pharma Private Limited Compare to Nearest Hydrochlorothiazide Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | ARISTO PHARMACEUTICALS PRIVATE LIMITED | $5.0M | 101 | 10 | $50.0K |
| 8 | AUROBINDO PHARMA LIMITED | $4.9M | 235 | 6 | $20.7K |
| 10 | WATSON PHARMA PRIVATE LIMITED ★ | $4.1M | 102 | 3 | $40.0K |
| 11 | MACLEODS PHARMACEUTICALS LIMITED | $3.9M | 188 | 21 | $20.9K |
| 9 | CAPLIN POINT LABORATORIES LIMITED | $3.5M | 69 | 6 | $50.0K |
Watson Pharma Private Limited ranks #10 among 403 Indian Hydrochlorothiazide exporters. Average shipment value of $40.0K compared to the market average of $295.9K. The closest competitors by value are ARISTO PHARMACEUTICALS PRIVATE LIMITED and AUROBINDO PHARMA LIMITED.
Which Indian Ports Ship Hydrochlorothiazide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,041 | 15.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 621 | 8.9% |
| NHAVA SHEVA SEA (INNSA1) | 621 | 8.9% |
| JNPT/ NHAVA SHEVA SEA | 493 | 7.1% |
| DELHI AIR | 319 | 4.6% |
| JNPT | 312 | 4.5% |
| Bombay Air | 252 | 3.6% |
| HYDERABAD ICD | 210 | 3.0% |
Geopolitical & Trade Policy Impact on Watson Pharma Private Limited's Hydrochlorothiazide Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Watson Pharma. The Israel-Iran conflict has disrupted key shipping routes in the Red Sea, leading to increased freight costs and extended transit times. These disruptions have particularly impacted time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and inventory management. (pharmaceuticalcommerce.com)
Conversely, the US-China trade tensions have opened avenues for Indian exporters to strengthen their foothold in the US market. India's pharmaceutical exports to the US surged by 20.4% to approximately $10.5 billion in FY25, despite challenges such as pricing pressures and regulatory scrutiny. (economictimes.indiatimes.com) This growth underscores the potential for companies like Watson Pharma to expand their presence in the US market.
The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, is poised to eliminate tariffs on pharmaceuticals, enhancing market access for Indian exporters. This development offers Watson Pharma an opportunity to increase its exports to the EU, provided it meets the stringent regulatory standards set by the European Medicines Agency (EMA). (en.wikipedia.org)
Watson Pharma Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. India has made significant strides in this area, with the number of FDA-approved manufacturing sites surpassing those in the US as of 2024. Instances of non-compliance have also decreased, reflecting improved adherence to quality standards. (business-standard.com) For Watson Pharma, maintaining and enhancing compliance with FDA, WHO GMP, and EMA standards is crucial to sustaining and expanding its export markets.
The evolving regulatory environment, including the EU's Falsified Medicines Directive, necessitates robust traceability and anti-counterfeiting measures. Watson Pharma must invest in advanced serialization and tracking systems to ensure compliance and maintain trust with international partners.
About Watson Pharma Private Limited
Watson Pharma Private Limited exports 14 products worth $63.4M. Beyond Hydrochlorothiazide, top products include Gabapentin, Alprazolam, Prednisone, Dapagliflozin, Simvastatin. View the complete Watson Pharma Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Hydrochlorothiazide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Hydrochlorothiazide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Watson Pharma Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 102 individual customs records matching Watson Pharma Private Limited exporting Hydrochlorothiazide, covering 59 formulations to 3 countries via 9 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 149+ countries, 1,130+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Hydrochlorothiazide Export Data from Watson Pharma Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Watson Pharma Private Limited's Hydrochlorothiazide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Watson Pharma Private Limited
Full Company Profile →
14 products · $63.4M total trade · 7 categories
Hydrochlorothiazide Stats
Company Overview
Top Products by Watson Pharma Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Watson Pharma Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Hydrochlorothiazide. For current shipment-level data, contact TransData Nexus.